The Atlas Arteria Group (ASX: ALX) share price is in focus today after Diamond Infraco 1 Pty Ltd, a subsidiary of IFM Global Infrastructure Fund, increased its takeover offer to $5.10 per security – a 17.8% premium to the pre-offer closing price. The improved bid has also removed several offer conditions, leaving only prescribed occurrences outstanding.
Image source: Getty Images
What did Atlas Arteria report?
- Offer price increased from $4.75 to $5.10 per security
- The new offer represents a 17.8% premium to the closing price on 24 April 2026
- Bidder's voting power in Atlas Arteria now stands at 34.59%
- The offer is unconditional except for 'no prescribed occurrences'
- Bidders authorised to acquire securities on-market at or below the offer price
What else do investors need to know?
The bidder has declared the $5.10 offer "best and final" in the absence of a competing proposal, meaning it won't be raised further unless another suitor emerges. Shareholders can also choose to sell on-market for T+2 settlement terms at or above the offer price, but should be aware that brokerage fees may apply.
Diamond Infraco has highlighted that the offer gives a cash certain value now, contrasted against the risks and uncertainty of Atlas Arteria's alternative plans, such as a potential Chicago Skyway sale. The company stressed that a sale has already been under consideration for over a year, with no firm outcome.
What's next for Atlas Arteria?
The offer remains open until 7:00pm on 25 June 2026, unless extended. If accepted, shareholders who go via the offer will generally receive payment within 21 days of the offer closing, while those selling on-market settle in two business days but forfeit further participation.
Looking ahead, the next key event will be the resolution of the sole remaining offer condition (no prescribed occurrences) and the board's recommendation. Shareholders are encouraged to review all documents and consider their options.
Atlas Arteria share price snapshot
Over the past 12 months, Atlas Arteria shares have declined 6%, trailing the S&P/ASX 200 Index (ASX: XJO) which has risen 3% over the same period.
